PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

First whale sighting contest begins Whatʻs your best guess? Whale season will be here in Hawaiʻi before you know it. When do ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary b ...

HighField Biopharmaceuticals’ new immuno-oncology drug molecule HF1K16 shows safe and signals efficacy in treating refractory metastatic cancers: Hanghou, China Wednesday, Septe ...

Overall, the Company believes that the results to date from the TAMARACK study indicate antitumor activity associated with vobra duo in mCRPC as demonstrated by the protocol-specified primary endpoint ...

Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 β/γ in combination ...

Among the giant election posters hanging in the streets of Cottbus, a city in eastern Germany often in the headlines for ...